Sweden · Healthcare · SEK
Reported figures and Equlion model projections for the next 5 years.
| Metric | 2025 (actual) | 2026 | 2027 | 2028 | 2029 | 2030 | Trend |
|---|---|---|---|---|---|---|---|
| ROE | -161.81% | 498.81% | 91.36% | 54.14% | 38.87% | 29.58% | |
| ROA | -122.98% | -368.71% | - | - | - | - | |
| Gross Margin | 100% | 100% | 100% | 100% | 100% | 100% | |
| Sector average | 16.85% | 17.71% | 17.71% | 17.71% | 17.71% | 17.71% | |
| Total Assets | SEK 9,928.00K | SEK 2,468.34K | SEK 2,836.54K | SEK 3,281.03K | SEK 3,658.20K |
Amounts in SEK (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for Disruptive Pharma AB (publ)? It covers the balance sheet, income statement and Equlion model projections.
| SEK 3,872.31K |
| Sector average | SEK 2,857,190.78K | SEK 2,900,240.60K | SEK 3,045,009.79K | SEK 3,280,286.42K | SEK 3,536,407.14K | SEK 3,762,908.71K |
|---|
| Net Income | -SEK 19,934.00K | -SEK 22,853.08K | -SEK 26,923.25K | -SEK 31,866.60K | -SEK 36,087.93K | -SEK 38,494.57K | |
|---|---|---|---|---|---|---|---|
| Sector average | -SEK 2,851.32K | -SEK 22,027.28K | -SEK 904.69K | -SEK 7,253.84K | -SEK 3,858.45K | -SEK 1,547.00K |
